An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson�s patients with L-dopa induced dyskinesias

To evaluate the long-term safety and tolerability of AFQ056 in patients with PD-LID as assessed by �Incidence and severity of adverse events and serious adverse events �Changes in vital signs, laboratory assessments, and ECGs �Changes in underlying symptoms of PD as measured by the UPDRS (Unified Parkinson�s Disease Rating Scale) part III (Motor Examination) and AEs potentially related to an exacerbation of the movement disorder of PD